Exendin-4 (a GLP-1 receptor agonist) prevented ferroptosis — a form of iron-dependent cell death — in diabetic kidney tubular cells by activating the AMPK pathway to restore healthy fat metabolism.
AMPK-ferroptosis axisExendin-4 activated AMPK to suppress iron overload and lipid peroxidation in diabetic kidney tubules
What the researchers found
Exendin-4 suppressed ferroptosis in diabetic kidney tubular cells by activating AMPK-fatty acid metabolism signaling, reducing iron overload and lipid peroxidation through macropinocytosis-dependent cellular uptake.
Why it matters
GLP-1 receptor agonists are already known to benefit kidney outcomes in diabetes, but the mechanisms have been unclear. This study reveals a specific protective pathway — suppression of ferroptosis via AMPK — that explains how these drugs protect kidneys beyond just lowering blood sugar and weight.
The numbers in context
Three pillars of tubular ferroptosis: iron reabsorption, lipid metabolism, and redox-active compound exposure.
How the study worked
Preclinical study using diabetic kidney models (in vitro and in vivo). Examined ferroptosis markers (GPX4, GSH, ACSL4, iron levels), AMPK signaling, fatty acid oxidation, and macropinocytosis pathways.
Who was studied
Mechanistic study of diabetic kidney tubular cells
What this study cannot tell us
Preclinical study using exendin-4, not the more commonly prescribed semaglutide or liraglutide. Results from cell and animal models may not fully translate to human diabetic kidney disease. The relative contribution of ferroptosis versus other cell death pathways in human DKD is not established.
How to read the evidence
Preliminary evidence from preclinical models. Demonstrates a plausible mechanistic pathway but lacks human clinical validation.
When this study was published
Published in 2024. Contributes to the rapidly growing understanding of GLP-1RA organ-protective mechanisms.
The bigger picture
As GLP-1 drugs like semaglutide and liraglutide are increasingly recognized for organ-protective effects beyond glucose control, understanding the specific mechanisms matters for optimizing treatment. This ferroptosis-prevention pathway could explain kidney benefits seen in large clinical trials and may lead to more targeted therapies.
Questions still open
- Do semaglutide and liraglutide suppress ferroptosis through the same AMPK-dependent mechanism?
- Can ferroptosis biomarkers be used to identify diabetic patients most likely to benefit from GLP-1RA kidney protection?
- Would combining GLP-1RAs with iron chelation therapy provide additive kidney protection?
Common questions
What is ferroptosis and why does it matter for diabetic kidneys?
Does this explain why GLP-1 drugs protect kidneys in clinical trials?
Read the original research
GLP-1 receptor agonist attenuates tubular cell ferroptosis in diabetes via enhancing AMPK-fatty acid metabolism pathway through macropinocytosis.
Biochimica et biophysica acta. Molecular basis of disease, 1870(4), 167060
Citation
Shen, Rui; Qin, Songyan; Lv, Yunhui; Liu, Dandan; Ke, Qingqing; Shi, Caifeng; Jiang, Lei; Yang, Junwei; Zhou, Yang. (2024). GLP-1 receptor agonist attenuates tubular cell ferroptosis in diabetes via enhancing AMPK-fatty acid metabolism pathway through macropinocytosis.. Biochimica et biophysica acta. Molecular basis of disease, 1870(4), 167060. https://doi.org/10.1016/j.bbadis.2024.167060